Roche Q1 2021 Sales Basel, 21 April 2021 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. Group Severin Schwan Chief Executive Officer Q1 2021 performance Outlook 5 Responding quickly and broadly to the pandemic SARS-CoV-2 Rapid Antigen Nasal Test Casirivimab + imdevimab (nAb cocktail) • Reliably identifies highly infectious individuals in 15 minutes • Emergency use ongoing in US/EU for mild/moderate COVID-19 (Sensitivity: 89.6% at Ct≤30; Specificity 99.1%) at high risk for progression to severe disease and/or hospitalization • Performance independently and externally validated by • Positive Ph III results in confirmatory outpatient treatment University of Heidelberg and Charité Berlin – Significant reduction in risk of hospitalization or death for both tested doses (2.4g & 1.2g) vs. placebo • In a meta-analysis1 across 74 studies2 the Roche SARS-CoV-2 Rapid Antigen Test achieved the highest overall sensitivity3 • Positive Ph III results in prevention setting – Significant reduction in risk of symptomatic infection among those in close contact with infected patient 1 Source: https://www.medrxiv.org/content/10.1101/2021.02.26.21252546v1; 2 30,000 samples; 3 across all patient subgroups 6 Q1 2021: Strong Diagnostics Division driving Group sales growth 2021 2020 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 10.6 12.3 -14 -9 Diagnostics Division 4.3 2.9 50 55 Roche Group 14.9 15.1 -1 3 CER=Constant Exchange Rates 7 Q1 2021: Successfully managing the transition in a difficult environment Group sales 6% 8% 7% growth (CER) 4% 3% Group 100% sales 10% 80% 35% 41% 60% 16% 40% 20% 28% 20% 29% 21% 0% Q1 17 Q1 18 Q1 19 Q1 20 Q1 21 Diagnostics Division Other pharma AHR New products1 CER=constant exchange rates; AHR=Avastin, Herceptin & MabThera/Rituxan; 1 Erivedge, Perjeta, Kadcyla, Gazyva, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, Xofluza, Polivy, Rozlytrek, 8 Phesgo, Enspryng, Evrysdi, casirivimab+imdevimab Q1 2021: Sales growth despite severe biosimilar impact New products accounting for 50% of Pharma sales Pharma sales mix +3% at CER Q1 2020 CHFm +880 33% 37% +1,538 -376 30% -641 Q1 2021 -1,614 22% 15,143 14,930 50% 28% Q1 2020 Pharma Pharma Pharma Diagnostics Fx Q1 2021 New products launched since 2012 new other Bx exposed Division Other products Herceptin + Rituxan + Avastin products 1 products products 2 Q1 values in reported CHFm, variances in CERm; 1 Erivedge, Perjeta, Kadcyla, Gazyva, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, Xofluza, Polivy, Rozlytrek, Phesgo, Enspryng, Evrysdi, 9 casirivimab+imdevimab; 2 Avastin, Herceptin, MabThera/Rituxan Q1 2021: Pandemic continues to impact business dynamics % CER 1st wave 2nd wave 3rd wave +60% +50% Pharmaceuticals +50% +55% • Continued severe impact from biosimilars and +40% COVID-19, lack of new patients starts in particular +32% +28% in cancer care +30% +25% +20% +18% +20% +24% Diagnostics +10% +7% +2% +5% • Routine business showing strong growth +0% -6% -7% -9% -4% • COVID-19 testing gaining further momentum -10% Q1'20 vs. Q2'20 vs. Q3'20 vs. Q4'20 vs. Q1'21 vs. Q1'19 Q2'19 Q3'19 Q4'19 Q1'20 Diagnostics Pharma Pharma New Products Growth rates at CER (Constant Exchange Rates) 10 Q1 2021 performance Outlook 11 Continuing to invest in innovation Diversifying the late stage pipeline & launching new systems Achievements in Q1 2021: Pharma Achievements in Q1 2021: Diagnostics New to Phase II Serum work area systems launches Brain shuttle gantenerumab in Alzheimer’s disease cobas® pure GABA Aa5 PAM in autism spectrum disorder Optimizing efficiency for small size laboratories HBV siRNA in chronic Hepatitis B tiragolumab + Tecentriq in 1L PD-L1+ mSCCHN New to Phase III ® fenebrutinib in RMS (2x Ph III) cobas pro (high throughput) Increasing scalability and flexibility rhPTX-2 in IPF Kadcyla + Tecentriq in 2L+ HER-2+ PD-L1+ mBC faricimab in branch & central RVO (2x Ph III) Neuroscience Infectious Diseases Immunology Oncology/Hematology Ophthalmology 12 2021 outlook confirmed Further growing top and bottom line Group sales growth1 • Low- to mid-single digit Core EPS growth1 • Broadly in line with sales growth Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER); based on the current assessment of the COVID-19 impact 13 Pharmaceuticals Division Bill Anderson CEO Roche Pharmaceuticals Q1 2021: Pharmaceuticals Division sales Sales still impacted by COVID-19 and biosimilars 2021 2020 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 10,600 12,262 -14 -9 United States 5,292 6,616 -20 -14 Europe 2,175 2,264 -4 -6 Japan 852 948 -10 -7 International 2,281 2,434 -6 0 CER=Constant Exchange Rates 15 Q1 2021: Continued portfolio rejuvenation Ocrevus 16% Hemlibra 33% Tecentriq 26% Casirivimab + Imdevimab n/a Actemra / RoActemra 22% Evrysdi n/a Kadcyla 17% Alecensa 14% Phesgo n/a Perjeta 2% Enspryng n/a Polivy 18% Gazyva -2% Esbriet -8% Lucentis -7% Xofluza -100% US Xolair -6% Tarceva -56% Europe TNKase / Activase -17% Tamiflu -83% Japan Herceptin -35% Avastin -40% International MabThera -46% CHFm -800 -400 0 400 Absolute values and growth rates at Constant Exchange Rates (CER) 16 Pharma growth dynamic excl. AHR* slowed down by COVID-19 Quarterly sales development Pharmaceuticals Division (excl. AHR) CHFm 9,000 8,000 Pharma other 7,000 Infectious diseases 6,000 Ophthalmology 5,000 Immunology 4,000 Hemophilia A Neuroscience 3,000 Oncology 2,000 1,000 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2017 2017 2017 2017 2018 2018 2018 2018 2019 2019 2019 2019 2020 2020 2020 2020 2021 2017 2018 2019 2020 2021 * AHR=Avastin, Herceptin, MabThera/Rituxan; all absolute values at Constant Exchange Rates (avg. FY 2020); “Pharma other” comprises the tail end products 17 Milestone achieved: 50% of Pharma sales are new products* Rolling filings for casirivimab/imdevimab and PDS started CHFm % of Pharma Sales 6,000 5,500 50% 5,000 37% 4,500 4,000 3,500 27% 3,000 2,500 19% 2,000 1,500 1,000 500 0 Q1 18 Q1 19 Q1 20 Q1 21 Erivedge Perjeta Kadcyla Gazyva Esbriet Cotellic Alecensa Tecentriq Ocrevus Hemlibra Xofluza Polivy Rozlytrek Phesgo Enspryng Evrysdi Casirivimab/Imdevimab * Venclexta sales are booked by partner AbbVie and therefore not included and Gavreto sales are initially booked by partner Blueprint and therefore not included; NME=new molecular entity 18 Q1 2021: Oncology -19% due to biosimilars & COVID-19 YoY CER growth HER2 franchise Phesgo • Kadcyla (+17%) with growth in all regions due to adjuvant BC HER2 franchise Herceptin Perjeta (+2%) -11% • Perjeta (+2%) with growth driven by International Kadcyla (+17%) • Successful Phesgo launch in US and EU on-going Avastin Avastin -40% Avastin franchise Tecentriq Tecentriq +26% • Biosimilar erosion in all regions Polivy (+18%) Hematology Hematology franchise* Rituxan -37% franchise • Venclexta: Strong growth in 1L AML Gazyva (-2%) Alecensa +14% • Gazyva (-2%): Stable sales in 1L CLL and 1L FL due to COVID-19 Cotellic • Polivy (+18%): Growth in R/R DLBCL; Ph III (POLARIX) results in 1L Cotellic + Zelboraf -30% DLBCL expected in H2 2021 Tarceva -56% Tecentriq • Growth driven by 1L SCLC, 1L TNBC and 1L HCC Rozlytrek +187% Alecensa CHFbn 0 1 2 3 • Growth driven by International CER=Constant Exchange Rates; Q1 2021 Oncology sales: CHF 5.1bn; CER growth -19% ; * Venclexta sales booked by AbbVie and therefore not included (FY-2020 sales of USD 1,337m); Polivy in collaboration with Seagen; BC=breast cancer; AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; FL=follicular lymphoma; R/R DLBCL=relapsed/refractory diffuse large B cell lymphoma; SCLC=small cell lung cancer; TNBC=triple negative breast cancer; HCC=hepatocellular carcinoma 19 Tecentriq overview: Growth driven by first-in-class indications Landmark results in adjuvant NSCLC announced Tecentriq Q1 update CHFm YoY